Clinical and experimental obstetrics & gynecology · 2007
Ovulation disorders: Part II. Anovulation associated with normal estrogen.
Редакционная статьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Check J H
Аннотация
PURPOSE: To present various types of anovulatory states associated with normal estrogen and various treatment options.
METHODS: Evaluation and treatment of various conditions including polycystic ovarian syndrome, hyperprolactinemia, congenital adrenal hyperplasia are discussed as are methods to prevent certain complications of these therapies.
RESULTS: Clomiphene citrate seems equally effective to gonadotropins at least for the first three cycles but has a frequent complication of adversely affecting the cervical mucus so intrauterine insemination is frequently needed. Glucocorticoid therapy and insulin receptor drugs can exert a primary or more commonly an ancillary benefit when used in combination with other follicle maturing drugs. Complications, e.g., adverse cervical mucus, luteinized unruptured follicle (LUF) syndrome, premature luteinization, luteal phase deficiency and treatment options are presented.
CONCLUSIONS: Vaginal progesterone can correct luteal phase problems, human chorionic gonadotropin (hCG) and follicle stimulation hormone (FSH) and gonadotropin releasing hormone (GnRH) agonists can help LUF syndrome and GnRH agonists and antagonists can help the complication of premature luteinization.
METHODS: Evaluation and treatment of various conditions including polycystic ovarian syndrome, hyperprolactinemia, congenital adrenal hyperplasia are discussed as are methods to prevent certain complications of these therapies.
RESULTS: Clomiphene citrate seems equally effective to gonadotropins at least for the first three cycles but has a frequent complication of adversely affecting the cervical mucus so intrauterine insemination is frequently needed. Glucocorticoid therapy and insulin receptor drugs can exert a primary or more commonly an ancillary benefit when used in combination with other follicle maturing drugs. Complications, e.g., adverse cervical mucus, luteinized unruptured follicle (LUF) syndrome, premature luteinization, luteal phase deficiency and treatment options are presented.
CONCLUSIONS: Vaginal progesterone can correct luteal phase problems, human chorionic gonadotropin (hCG) and follicle stimulation hormone (FSH) and gonadotropin releasing hormone (GnRH) agonists can help LUF syndrome and GnRH agonists and antagonists can help the complication of premature luteinization.